tag:blogger.com,1999:blog-7857054149675424609.post7004343363000683983..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: RXi Reports 43% CTGF Knockdown in Multi-Dose Dermal Anti-Scarring TrialDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger10125tag:blogger.com,1999:blog-7857054149675424609.post-6950923763600622162013-08-10T08:51:04.998+00:002013-08-10T08:51:04.998+00:00you're wrong dude
Must read this article: RXi...you're wrong dude<br /><br />Must read this article: RXi Pharma Hopes For a Quick Breakthrough<br /><br />By Steve Haas | More Articles<br />July 27, 2013<br />Page 2 of 5view all<br />2. In light of your Phase 1 results, you may have noticed the results Alnylam (NYSE:ALNY) presented last week for their clinical program. Where do you place their 80 percent reduction in protein in context withStanleyhttp://www.wall-street.cznoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-30280858604667205892013-08-01T22:45:25.794+00:002013-08-01T22:45:25.794+00:00From what I understand Dirk from the CEO of RXII i...From what I understand Dirk from the CEO of RXII in the interview Excaliard/Pfizer phase 1 of 30% to 40% gene knockdown was with a higher dosing regimen than RXII. Meaning RXII achieved slightly higher at 43% with lower dosing than Excaliard. <br /><br />Also I understood what the CEO of RXII was saying as comparison between RXII and alnylam. in Alnylam you want the high gene knockdown of 80% orAnonymoushttps://www.blogger.com/profile/15272090885302748605noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-65403107420251812392013-07-21T09:18:58.669+00:002013-07-21T09:18:58.669+00:00Yes, I listened to it and was quite surprised abou...Yes, I listened to it and was quite surprised about the apparently weak knockdown of the Excaliard/Pfizer compound. Do you know the dosing schedule for those studies? Maybe they optimized subsequently to improve knockdown?<br /><br />If 30-40% was really the knockdown number for the Excaliard compound, it raises the question whether everything is an off-target phosphorothioate antisense class Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-34971528118310854042013-07-20T14:13:01.956+00:002013-07-20T14:13:01.956+00:00Dirk did you listen to the RXI CEO interview with ...Dirk did you listen to the RXI CEO interview with CEO and Griffin securities? The CEO mentioned that Excaliard achieved 30 to 40% CTGF reduction in their phase 1 testing. It's under events and webcast on official RXII site. So it seems Excaliard achieved less Results on their phase 1 testing.Anonymoushttps://www.blogger.com/profile/15272090885302748605noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-63010600470239575782013-07-17T17:52:22.283+00:002013-07-17T17:52:22.283+00:00Looks like Alnylam is in a strong financial positi...Looks like Alnylam is in a strong financial position to gobble up one of those companies. Any predictions?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-77694738803261617972013-07-13T14:45:33.170+00:002013-07-13T14:45:33.170+00:00I've also looked in vain for Excaliard's k...I've also looked in vain for Excaliard's knockdown numbers from the clinical studies. I'm long RXi, but feel misled by their single-dose knockdown claim.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-21533068919817897642013-07-13T13:29:32.694+00:002013-07-13T13:29:32.694+00:00Dirk to add another question. I see that RXII is g...Dirk to add another question. I see that RXII is giving hard numbers for their positive results. In the article you claimed that Excaliard would know the right percentage of knockdown. <br /><br />But when I look online for Excaliard phase 2 positive trials they don't list any percentage of gene knockdown at all. They just say better than placebo but they don't give a hard number. So how Anonymoushttps://www.blogger.com/profile/15272090885302748605noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-72078439509010501062013-07-12T22:53:14.436+00:002013-07-12T22:53:14.436+00:00I'm reminded of Phase I news back around 2008 ...I'm reminded of Phase I news back around 2008 that spiked the share price of Alnylam above $34 (I sold most at that time and bought Tekmira). The Phase I news turned out to be much ado about nothing, so the price dropped below $7. Their treatment of Tekmira, their settlement after denying their actions, the trouble they caused with their lies...have ruined me on this company's management.experiencedmentornoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-25549384062927998982013-07-12T22:27:54.282+00:002013-07-12T22:27:54.282+00:00Dirk not bad for phase 1 also they mentioned in th...Dirk not bad for phase 1 also they mentioned in their phase 2 studies they will optimize the doses more! So couldn't they achieve better results with higher dosing? Anyways I notied you were always disclosing that you were long on RXII! are you still long RXII and do you believe in the self delivery technology after today's results shown?Anonymoushttps://www.blogger.com/profile/15272090885302748605noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-91407597854041450602013-07-12T21:54:07.283+00:002013-07-12T21:54:07.283+00:00How much money have you lost on ALNY?How much money have you lost on ALNY?Anonymoushttps://www.blogger.com/profile/06781760292756178582noreply@blogger.com